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Postoperative wound drainage reinfusion reduces the frequency of homologous 
blood transfusion. The salvaged blood is depleted of coagulation factors but may 
contain platelets and leukocytes which are activated, and therefore potentially 
procoagulant. We ascertained the degree of activation of platelets and leukocytes 
in salvaged blood and asked whether their infusion produced any measurable 
effect on patients’ coagulation system.  We prospectively randomized 24 patients 
who had total knee arthroplasties to reinfusion of salvaged autologous blood (n = 
12) or a standard drain with no reinfusion (n = 12). Analysis of the salvaged 
blood showed marked activation of platelets as shown by their expression of P-
selectin, CD40 ligand, and Factor V/Va, and as increased numbers of platelet-
derived microparticles. After reinfusion there was no measurable effect on 
activation markers of circulating platelets or leukocytes but there was a decrease 
in platelet count in the reinfused group compared with the control group. Levels 
of prothrombin fragment F 1+2 (suggesting thrombin formation) increased in 
the reinfused group compared with control group, possibly indicating activation 
of coagulation systemically. The platelets and leukocytes in salvaged blood are 
markedly activated and their reinfusion causes a decrease in platelet count in the 
recipient and a possible increase in thrombin generation potentially favoring 
thrombosis. 
 
 
Level of Evidence: Level II Therapeutic study. See the Guidelines for Authors 
for a complete description of levels of evidence. 
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Blood transfusions are common after joint replacement surgery, although the 
incidence has decreased because of measures such as transfusion protocols, 
normovolemic hemodilution, preoperative erythropoietin, and antifibrinolytic drugs.3 
Postoperative wound drainage reinfusion reduces the frequency of homologous blood 
transfusion between 67% and 91%.10,13,16,17. Reinfused drainage contains low levels of 
clotting factors such as Factor VIII and fibrinogen.4-6,8  One study examined the effect 
of reinfusion of postoperative wound drainage blood on leukocyte-derived and 
platelet-derived bioactive substances and on blood coagulation and concluded 
“reinfusion of drainage blood did not change the coagulative capacity of the 
patients.”8   
 
Platelet activation has been associated with the development of venous thrombosis.  
Radiographically confirmed deep venous thrombosis (DVT) in patients after total 
knee arthroplasty (TKA) is associated with an increased platelet activation marker, P-
selectin.19   
 
We ascertained whether platelets and leukocytes had increased activation in salvaged 
blood and whether their infusion produced any measurable effect on patients’ 
coagulation system.   
. 
MATERIALS AND METHODS 
We prospectively enrolled 24 patients with osteoarthritis having primary TKAs in a 
prospective, consecutive, systematically allocated study. The patients were divided 
into two groups: a treatment group and a control group. Patients experience a decrease 
in platelets of approximately 30% immediately after surgery.18 However, an increase 
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in the amount of this decrease attributable to reinfusion may indicate an increase in 
clotting potential. To detect a substantial difference between the two groups in the 
decrease in platelet count of 50% with 80% power, 11 patients were required in each 
group.  To allow for dropout or testing anomalies, a sample size of 12 patients was 
deemed necessary.  The treatment group (12 patients) received autologous salvaged 
blood from a reinfusion drain (CBCII ConstaVac, Stryker Instruments, Kalamazoo, 
MI).  A control group (12 patients) had TKA with a standard drain (Bellovac, Astra, 
Molndal, Sweden). The patients were matched for age and gender. Demographic data 
between the groups did not differ (Table 1).  Intake of any antiplatelet drugs was 
discontinued at least 7 days before surgery. A tourniquet was used routinely and was 
released after wound closure and application of pressure dressings. 
 
The CBCII ConstaVac is a closed blood recovery system used to collect, filter, and 
reinfuse autologous blood. The blood first passes through a 240-μm filter before 
entering an 800-mL plastic container. This first filter removes particles in the blood 
such as bone fragments, clotted blood, and fat particles. No anticoagulant is used. 
During reinfusion, the blood passes through a 40-μm pore filter before being returned 
to the patient. This filter removes additional debris while allowing platelets, 
leukocytes, and red cells to pass. The last 100 mL of shed blood remained in the 
container and was not reinfused. The transfusion of shed blood collected from the 
wound postoperatively was started 4 hours after initiating collection.6,15 
 
Systemic blood samples from the patients in the treatment group were taken after 
surgery on three occasions; 1 hour before salvaged blood reinfusion (A), 1 hour after 
completion of reinfusion (B), and the following day. The reinfusion was initiated 4 
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hours after surgery and was completed within ½ to 1 hour. A separate sample was 
acquired from the salvaged blood, after it had passed the final filter, at the time of 
reinfusion.  
 
The blood samples of the control group were taken at 3 (A) and 5.5 (B) hours 
postoperatively and the following day to correspond to the time samples were taken 
from the treatment group.  To prevent activation of blood during the drawing process, 
approximately 5 mL of blood was collected in a plain tube to clear the line. This 
specimen was discarded. Blood (2.7mL) was drawn into Vacutainer tubes (Becton 
Dickinson, NJ) containing 0.109 mol/L buffered trisodium citrate. For measurements 
of patients’ full blood count, venous blood was collected in a Vacuette tube (Greiner 
bio-one, Kremsmünster, Austria) containing EDTA K2.  Citrated blood samples from 
each patient at times A and B and their salvage at the completion of reinfusion were 
collected. These were immediately centrifuged at 3000 g for 10 minutes and the 
plasma stored in liquid nitrogen until testing.  
 
The European Working Group on Clinical Cell Analysis recommends using fixation 
after staining or counting cells promptly.14 The latter option has been used. The 
citrated blood was diluted 1:6 in Dulbecco’s phosphate buffered saline (PBS) (CSL, 
Parkville, Victoria, Australia) containing 2% fetal bovine serum and 0.1% sodium 
azide. Platelets were selected by forward scatter and side scatter and by positive 
staining with CD42a (BD Biosciences, San Jose, CA) that targets GP IX and GP 1b-
IX-V common to all platelets. Platelet-derived microparticles were selected similarly, 
their size being less than 0.3 μm as indicated by the side-scatter value. This value was 
established by calibration with 0.2 μm, 0.5 μm, and 0.71 μm polymer microspheres 
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(Duke Scientific Corporation, Palo Alto, CA).  Platelet activation markers included 
activated GPIIb/IIIa (PAC1) (BD Biosciences), P-selectin (CD62P) (BD Biosciences), 
factor V/Va (American Diagnostica Inc, Greenwich, CT), and CD40 ligand (CD154) 
(BD Biosciences).15 Monocytes, neutrophils, and lymphocytes were selected by 
forward scatter and side scatter plus positive staining with CD14 (BD Biosciences) for 
the monocytes or CD45 (BD Biosciences) for the neutrophils. Leukocyte activation 
markers were platelet-monocyte aggregates, and platelet-neutrophil aggregates, using 
CD42a to identify adherent platelets. Other leukocyte markers were MAC-1 (CD11b), 
tissue factor (American Diagnostica Inc), and P-selectin glycoprotein ligand-1 (CD 
162) (BD Biosciences). 
 
The flow cytometer used was a BD Biosciences FACScan with a 488-nm argon-ion 
laser performing 3-color analysis. The CELLQuest program was used to analyze the 
data. Daily quality control of the flow cytometer was performed with CaliBRITE 3 
beads (BD Biosciences). 
 
A prothrombin fragment F 1+2 immunoassay was performed using the Enzygnost kit 
(Dade-Behring, Marburg, GmbH, Germany). The frozen plasma samples were thawed 
at 37°C for 5 minutes before testing. Full blood counts were performed on a Coulter 
Gen S System 2 analyzer (Coulter Corporation, Miami, FL). 
 
Data were not normally distributed (Kolmogorov-Smirnov test for normality), 
therefore nonparametric tests were applied. Values are expressed as medians 
(interquartile ranges). For comparison of paired data the Wilcoxon signed-rank test 
was used. The Mann-Whitney U test was used for analyses of data in independent 
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groups. Probability was considered significant when p < 0.05.  A Bonferroni 
correction was applied where appropriate. 
 
RESULTS 
P-selectin, Factor V/Va, CD40 ligand, and platelet-derived microparticles were 
increased in salvaged blood compared to the patients’ blood 1 hour before reinfusion 
(Fig 1). The platelet-leukocyte activation markers; platelet-monocyte aggregates, and 
platelet-neutrophil aggregates in the salvaged blood of the treatment group were 
greater than in systemic blood at time- A (p = 0.005 and 0.003, respectively). 
Monocyte expression of MAC-1, tissue factor, and P-selectin glycoprotein ligand-1 in 
the salvaged blood of the treatment group were greater than in the patients’ circulation 
before reinfusion (p = 0.005, 0.003, and 0.008, respectively). Neutrophil expression of 
MAC-1, tissue factor, and P-selectin glycoprotein ligand-1 were similarly greater in 
the salvaged blood (p = 0.003, 0.006, and 0.008, respectively). One hour after infusion 
(B), the patients in the reinfused group had a greater increase (p = 0.002) in 
prothrombin fragment F 1+2 than the control group (Table 2). The salvaged blood had 
high levels of prothrombin fragment F 1+2 (median of 1060 [963-1347]) nmol/L.  
 
One hour after reinfusion, the median platelet count decreased from preinfusion levels 
(p = 0.004) whereas the control group showed no change (p = 0.168) (Table 3). On 
the first postoperative day, the median platelet count of the reinfused group showed an 
additional and greater decrease from preinfusion levels (p = 0.002) than the decrease 
in the control group (p = 0.019).  The reinfusion of autologous salvaged blood did not 
affect platelet activation or leukocyte markers in the patients’ circulation. 
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In the patients who had reinfusion, the salvaged blood had a lower hemoglobin, 
hematocrit, platelet count, leukocyte count, neutrophil count, and monocyte count 
than the systemic blood (Table 4). Reinfusion produced an increase (p = 0.01) in the 
patients’ median (interquartile range) hemoglobin from a level before reinfusion of 
114 g/L (104–131 g/L) to 119 g/L (104–131 g/L) 1 hour after the end of reinfusion. 
The median hemoglobin levels in the control group at the same times were 
unchanged, being 111g/L (102-117 g/L) and 112 g/L (99–120 g/L) at the times 
corresponding to before and after reinfusion, respectively.  
 
DISCUSSION 
Autologous salvaged blood differs from circulating blood regarding platelet and 
leukocyte activation and full blood count. The reinfusion of autologous salvaged 
blood to patients having a TKA does not lead to increased activation of circulating 
platelets and leukocytes but may cause activation of coagulation in the recipient. We 
therefore assessed hematologic laboratory parameters in patients having TKAs and 
receiving autologous reinfusion.   
 
The major limitation of this study was that the small number of patients recruited 
prevented us from making clinically significant findings due to the low incidence of 
DVT and PE. However, we did not intend to ascertain potential clinical thrombotic 
events (DVT or pulmonary embolism) or to compare transfusion rates. 
In spite of the small numbers we were able to demonstrate a significant effect of 
reinfusion on the physiological factors in the salvaged blood.  
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. An additional limitation was the difficulty in interpreting the importance of the 
increase in prothrombin fragment F 1+2 after reinfusion in relation to its indication of 
the patients’ endogenous thrombin generation due to the high levels of prothrombin 
fragment F 1+2 in the salvage.   
 
In accordance with previous research,4 shed blood had lower hemoglobin, hematocrit, 
leukocytes, and platelets than circulating blood. 
 
Our data shows the degree of activation of platelets and formation of platelet-
leukocyte aggregates in blood salvaged after TKA is increased compared with these 
variables in patients’ circulation 1 hour before reinfusion. Increased platelet and 
leukocyte activation markers in the circulation are associated with systemic 
thrombosis. Yang et al19 reported an increased platelet activation marker, P-selectin, 
after TKA is associated with increased radiographically confirmed DVT. Activation 
of platelets causes their shedding of vesicles, termed platelet-derived microparticles. 
Procoagulant platelet-derived microparticles may have an important role in the 
assembly of the components of the coagulation system.12 Our study showed 
substantial amounts of microparticles are added to the patients’ circulation with the 
salvaged blood. Platelet activation also causes a change in the glycoprotein IIb/IIIa 
receptor complex on the platelet, making it receptive to fibrinogen that provides a 
ligand for platelet-to-platelet aggregation.9 Platelet adhesion to the endothelium or 
immobilized fibrinogen via GP IIb/IIIa up-regulates the CD40 ligand, making it part 
of the signaling system in the inflammatory response.7 
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Increases in levels of platelet-monocyte aggregates have been associated with acute 
myocardial infarction.11 Increased levels of platelet-derived microparticles are linked 
to the development of cerebrovascular events.8 Blood draining from the surgical site 
and into the drain bottle may have the thrombotic process initiated with platelets 
being activated by exposure to thrombin and collagen. The activated platelets release 
the procoagulant contents of their alpha granules, thereby exposing P-selectin on the 
alpha granule membrane, which binds to P-selectin glycoprotein ligand-1 on 
leukocytes forming platelet-leukocyte aggregates. Platelet activation also releases 
platelet-derived microparticles that provide a platform for the coagulation cascade 
binding factors such as factor V/Va.1 Tissue factor is a potent procoagulant and P-
selectin promotes its production from monocytes.2 Our data show evidence of all 
these processes in the drainage blood. 
 
Reinfusion of activated blood did not lead to activation of the patients’ circulating 
platelets and leukocytes. This may be explained by the small amount of reinfused 
blood compared with the total volume of blood in the patients’ circulation. In 
addition, the concentration of platelets and, to a lesser extent, the leukocytes in the 
salvaged blood are low compared with those in the patients’ circulation.  
 
Our data suggest tissue factor expressed on the monocytes and neutrophils was 
introduced to the patients’ circulation with the salvage blood. Tissue factor initiates 
the extrinsic coagulation pathway, with eventual conversion of prothrombin to the 
enzyme thrombin that changes fibrinogen to the fibrin clot. This conversion releases 
prothrombin fragment F 1+2 so plasma levels provide a measure of clot formation. 
Before reinfusion, the treated and control groups showed evidence of increased 
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postoperative thrombin generation, the prothrombin fragment F 1+2 levels being 2 to 
21 times the upper limit of the established reference range of 0.4 to 1.1 nmol/L. This 
is most likely a product of the surgery. Prothrombin fragment F 1+2 has a half-life of 
1.5 hours and would have been cleared to a degree 1 hour after the end of reinfusion. 
Also, it was diluted approximately 1:10 in the patients’ circulation. One hour after the 
end of reinfusion, when compared with the control group, there was an increase in 
prothrombin fragment F 1+2 levels in the circulation of the treated group. Although 
this increase may be partly explained by prothrombin fragment F 1+2 being reinfused 
with the salvaged blood rather than being generated endogenously, the levels in 
systemic blood for individuals did not correlate with the F1+2 levels in the salvaged 
blood they received, suggesting reinfusion may have caused additional thrombin 
formation.  
 
Reinfusion led to a 14.2% decrease in the platelet count 1 hour after the reinfusion as 
compared to the 2.5% decrease observed in the control group. This greater loss of 
platelets may be attributable to consumption brought about by the initiation of 
coagulation by reinfusion. 
 
An increased activation and coagulability of the blood in drainage bags was observed 
in previous research8, although we used parameters not studied previously. We are 
unaware of previous reports of a systemic effect of reinfusion of autologous drainage 
blood. In particular, the rate of thrombotic complications, including DVT and 
pulmonary embolisms, in patients having TKAs where autologous reinfusion has been 
used, has not been reported with this or any other drainage system.  Though we have 
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shown systemic effects on coagulation factors, we have not been able to determine if 
these changes may lead to a clinically relevant increase in DVT or PE. 
 
The reinfusion of autologous salvaged blood to patients having a TKA does not lead 
to increased activation of circulating platelets and leukocytes but as noted earlier may 
activate coagulation in the recipient as suggested by a decrease in platelet count and 
increased levels of prothrombin fragment F 1+2. Although there are measurable 
systemic effects we do not know whether these effects lead to increased adverse 
clinical events. These theoretical clinical risks of reinfusion need to be weighed 
against the known risks of higher allogenic transfusion rates.
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Legends 
Fig 1. Measurements of platelet activation markers by flow cytometry reveal strongly 
significant increases in platelet activation in salvaged blood as shown by platelet 
expression of P-selectin, Factor V/Va, Cd40 ligand, and increased numbers of 
platelet-derived microparticles. The columns represent the median values and the 
error bars represent the 25th and 75th percentiles; p is the significance of the 
difference between circulating and salvaged blood.  
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TABLE 1. Demographic Data 
Parameter Measured Treatment Group 
(n = 12) 
Control Group 
(n = 12) 
Female 7 9 
Age (years) 72 (65–74) 74 (65–82) 
Weight (kg) 84 (76–94) 82(68–89) 
Preoperative hemoglobin (g/L) 138 (115–148) 133 (122–136) * 
Preoperative hematocrit 0.41 (0.36–0.44) 0.38 (0.36–0.42) * 
Preoperative platelet count (x109/L) 254 (213–276) 271 (220–286) * 
Preoperative white blood cell count 
(x109/L) 
6.9 (5.8–8.6) 7.8 (6.4–8.8) * 
Preoperative APTT1 (sec) 28 (26–31) 25 (23–28) 
Operation time (min) 89 (79–115) 86 (76–103) 
Blood loss (mL) 800 (490–1058) 600 (445–806) 
Reinfused blood (mL) 475 (400–600) – 
Hospital stay (days) 7.5 (6–10) 7 (6–9) 
Data are expressed as median (interquartile ranges); * n = 11; APTT = activated partial thromboplastin 
time 
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TABLE 2. Prothrombin Fragment F 1+2 Levels Measured One Hour Before and One 
Hour After the Completion of Reinfusion . The Control Group Measurements Were 
Made at Corresponding Time Points Postoperatively.  
 
Parameter Measured One Hour Before One Hour After p Value 
 Reinfused Control Reinfused Control  
Prothrombin fragment 
F  1+2 (nmol/L) 
4.6  
(2.6–9.2) 
3.3 
(2.6–4.4) 
24.3  
(21.4–38.5) 
3.7 
(2.9–5.0) 
0.002 
Data are expressed as median (interquartile ranges). p = significance of the difference of the change in 
level from before reinfusion to after reinfusion time points between reinfusion and control groups. 
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TABLE 3. Patients’ Platelet Count and Haemoglobin One Hour Before and One Hour 
After the Completion of Reinfusion and the Next Day. The Control Group 
Measurements Were Made at Corresponding Time Points Postoperatively. 
  
 One Hour Before One Hour After Next Day 
Parameter 
Measured 
Reinfused Control Reinfused Control Reinfused Control 
Platelets 
(x109/L) 
211 
(184-230) 
236 
(175-281) 
181 
(159-218) 
230 
(168-259) 
163 
(156-198) 
212 
(175-224) 
 
Hemoglobin 
(g/L) 
114 
(104-131) 
111 
(102-117) 
119 
(110-131) 
112 
(98-120) 
105 
(96-118) 
96 
(89-106) 
 
Data are expressed as medians (inter-quartile ranges).  
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TABLE 4. Full Blood Count of the Patient Before Reinfusion and of the Salvaged 
Blood 
 
Parameter Measured Patients Before 
Reinfusion (n = 12) 
Patients’ Salvaged 
Blood (n = 12) 
p Value
Haemoglobin (g/L) 114 (104–131) 89 (63–111) 0.003* 
Hematocrit 0.34(0.31–0.39) 0.26 (0.18–0.32) 0.003* 
Platelet count (x109/L) 211 (184-230) 31 (21-49) 0.002* 
Leucocyte count (x109/L) 12.5 (10.5–14.1) 4.7 (2.5-6.3) 0.002* 
Neutrophils count (x109/L) 10.90 (9.47–13.12) 2.90 (1.95–4.52) 0.002* 
Monocytes count (x109/L) 0.30 (0.23–0.65) 0.10 (0.00–0.2) 0.018 
Data are expressed as medians (interquartile ranges); p=significance of the difference between patients circulating blood and 
their salvaged blood; *significant after Bonferroni’s correction (p < 0.007) 
 
 
